- Clinical effect of abiraterone acetate in Korean patients with metastatic castration-resistant prostate cancer according to duration of androgen deprivation therapy
-
Kim KB, Jo JK, Ahn S, Lee S, Jeong SJ, Hong SK, Byun SS, Lee SE
- KMID: 2164409
- Korean J Urol.
- 2015 Aug;56(8):580-586.
- doi: 10.4111/kju.2015.56.8.580
PURPOSE: Few data are available concerning the clinical outcome of abiraterone acetate treatment in patients with metastatic castration-resistant prostate cancer (mCRPC) in terms of the duration of androgen deprivation therapy... -
- CITED
-
- Close
- SHARE
-
- Close
- ATP-Based Chemotherapy Response Assay in Primary or Recurrent Ovarian and Peritoneal Cancer
-
Lee M, Kim SW, Nam EJ, Cho H, Kim JH, Kim YT, Kim S
- KMID: 2070217
- Yonsei Med J.
- 2014 Nov;55(6):1664-1671.
- doi: 10.3349/ymj.2014.55.6.1664
PURPOSE: To investigate chemosensitivity with an adenosine triphosphate-based chemotherapy response assay in patients with epithelial ovarian or peritoneal cancer according to tumor histology, grade, and disease status. MATERIALS AND METHODS: One... -
- CITED
-
- Close
- SHARE
-
- Close
- Survival Outcomes of Concurrent Treatment with Docetaxel and Androgen Deprivation Therapy in Metastatic Castration-Resistant Prostate Cancer
-
Jang HS, Koo KC, Cho KS, Chung BH
- KMID: 2374150
- Yonsei Med J.
- 2016 Sep;57(5):1070-1078.
- doi: 10.3349/ymj.2016.57.5.1070
PURPOSE: Docetaxel-based chemotherapy (DTX) improves overall survival (OS) of men with metastatic castration-resistant prostate cancer (mCRPC). Considering the potential existence of androgen receptors that remain active at this stage, we... -
- CITED
-
- Close
- SHARE
-
- Close
- Docetaxel Chemotherapy of Korean Patients with Hormone-refractory Prostate Cancer: Comparative Analysis between 1st-line and 2nd-line Docetaxel
-
Joung JY, Jeong IG, Han KS, Kim TS, Yang SO, Seo HK, Chung J, Cho KS, Lee KH
- KMID: 2158196
- Yonsei Med J.
- 2008 Oct;49(5):775-782.
- doi: 10.3349/ymj.2008.49.5.775
PURPOSE: This study was undertaken to investigate the outcomes associated with docetaxel treatment of Korean patients with hormone-refractory prostate cancer (HRPC) and to compare its clinical efficacies in 1st and... -
- CITED
-
- Close
- SHARE
-
- Close
